Abstract
Diacylglycerol (DAG) kinase (DGK) modulates the balance between the two signaling lipids, DAG and phosphatidic acid (PA), by phosphorylating (consuming) DAG to yield PA. Ten mammalian DGK isozymes have been identified to date. In addition to two or three cysteine-rich C1 domains (protein kinase C-like zinc finger structures) commonly conserved in all DGKs, these isoforms possess a variety of regulatory domains of known and/or predicted functions, such as a pair of EF-hand motifs, a pleckstrin homology domain, a sterile α motif domain, a MARCKS (myristoylated alaninerich C kinase substrate) phosphorylation site domain and ankyrin repeats. Recent studies have revealed that DGK isozymes play pivotal roles in a wide variety of mammalian signal transduction pathways conducting growth factor/ cytokine-dependent cell proliferation and motility, seizure activity, immune responses, cardiovascular responses and insulin receptor-mediated glucose metabolism. It is suggested that several DGK isozymes can serve as potential drug targets for cancer, epilepsy, autoimmunity, cardiac hypertrophy, hypertension and type II diabetes. Unfortunately, there are no DGK isozyme-specific inhibitors/activators at present. Development of these compounds is eagerly awaited for the development of novel drugs targeting DGKs.
Keywords: Protein kinase C, guanyl nucleotide-releasing protein, GTPase-activating protein, target of rapamycin, phosphatidylinositol- 4-phosphate 5-kinase, R59949, sphingosine, calcium
Current Drug Targets
Title: Diacylglycerol Kinases as Emerging Potential Drug Targets for a Variety of Diseases
Volume: 9 Issue: 8
Author(s): Fumio Sakane, Shin-ichi Imai, Masahiro Kai, Satoshi Yasuda and Hideo Kanoh
Affiliation:
Keywords: Protein kinase C, guanyl nucleotide-releasing protein, GTPase-activating protein, target of rapamycin, phosphatidylinositol- 4-phosphate 5-kinase, R59949, sphingosine, calcium
Abstract: Diacylglycerol (DAG) kinase (DGK) modulates the balance between the two signaling lipids, DAG and phosphatidic acid (PA), by phosphorylating (consuming) DAG to yield PA. Ten mammalian DGK isozymes have been identified to date. In addition to two or three cysteine-rich C1 domains (protein kinase C-like zinc finger structures) commonly conserved in all DGKs, these isoforms possess a variety of regulatory domains of known and/or predicted functions, such as a pair of EF-hand motifs, a pleckstrin homology domain, a sterile α motif domain, a MARCKS (myristoylated alaninerich C kinase substrate) phosphorylation site domain and ankyrin repeats. Recent studies have revealed that DGK isozymes play pivotal roles in a wide variety of mammalian signal transduction pathways conducting growth factor/ cytokine-dependent cell proliferation and motility, seizure activity, immune responses, cardiovascular responses and insulin receptor-mediated glucose metabolism. It is suggested that several DGK isozymes can serve as potential drug targets for cancer, epilepsy, autoimmunity, cardiac hypertrophy, hypertension and type II diabetes. Unfortunately, there are no DGK isozyme-specific inhibitors/activators at present. Development of these compounds is eagerly awaited for the development of novel drugs targeting DGKs.
Export Options
About this article
Cite this article as:
Sakane Fumio, Imai Shin-ichi, Kai Masahiro, Yasuda Satoshi and Kanoh Hideo, Diacylglycerol Kinases as Emerging Potential Drug Targets for a Variety of Diseases, Current Drug Targets 2008; 9 (8) . https://dx.doi.org/10.2174/138945008785132394
DOI https://dx.doi.org/10.2174/138945008785132394 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polypharmacy in Chronic Neurological Diseases: Multiple Sclerosis, Dementia and Parkinson’s Disease
Current Pharmaceutical Design R-Type Voltage-Gated Ca<sup>2+</sup> Channels in Cardiac and Neuronal Rhythmogenesis
Current Molecular Pharmacology Brain Adaptation to Stressful Stimuli: A New Perspective on Potential Therapeutic Approaches Based on BDNF and NMDA Receptors
CNS & Neurological Disorders - Drug Targets Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis
Current Neuropharmacology A Synopsis of Nano-Technological Approaches Toward Anti-Epilepsy Therapy: Present and Future Research Implications
Current Drug Metabolism The Design of Multi-target Drugs to Treat Cardiovascular Diseases: Two (or more) Birds on One Stone
Current Topics in Medicinal Chemistry MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Probiotics/Prebiotics in Viral Respiratory Infections: Implication for Emerging Pathogens
Recent Patents on Biotechnology Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology Types of Voltage-Gated Calcium Channels: Molecular and Electrophysiological Views
Current Hypertension Reviews Reactive Astrocytes as Potential Manipulation Targets in Novel Cell Replacement Therapy of Parkinsons Disease
Current Drug Targets ABC Transporters in Extrahepatic Tissues: Pharmacological Regulation in Heart and Intestine
Current Medicinal Chemistry Update on Pharmacological Treatment of Progressive Myoclonus Epilepsies
Current Pharmaceutical Design Neurotoxic and Neuroactive Compounds from Cnidaria: Five Decades of Research….and More
Central Nervous System Agents in Medicinal Chemistry Editorial: Look for Changes in 2016
Current Molecular Medicine An Overview of the Selectivity and Efficiency of the Bacterial Carbonic Anhydrase Inhibitors
Current Medicinal Chemistry Protein-Energy Malnutrition Alters Hippocampal Plasticity-Associated Protein Expression following Global Ischemia in the Gerbil
Current Neurovascular Research Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Antiepileptic Drugs (AEDs) Polypharmacy Could Lead to Buried Pharmacokinetic Interactions due to CYP450
Drug Metabolism Letters Review of Antibiotic and Non-Antibiotic Properties of Beta-lactam Molecules
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry